Two polymorphisms in the fracalkine receptor CX3CR1 are not associated with peripheral arterial disease

Atherosclerosis

Volumn 166, Issue 2, 2003, Pages 339-343

  Gugl, Alexander ^a,c   Renner, Wilfried ^a   Seinost, Gerald ^a   Brodmann, Marianne ^a   Pabst, Edmund ^a   Wascher, Thomas C ^a   Paulweber, Bernhard ^b   Iglseder, Bernhard ^b   Pilger, Ernst ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b Landeskliniken Salzburg ^*  (Austria)

^c UNIVERSITY HOSPITAL GRAZ   (Austria)

Author keywords

CX3CR1; Epidemiology; Fractalkine; Peripheral arterial disease; Polymorphism

Indexed keywords

CHEMOKINE RECEPTOR; FRACALKINE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTERY DISEASE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE COURSE; DOCUMENTATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGRESSION ANALYSIS;

AGE DISTRIBUTION; AGED; ALLELES; BASE SEQUENCE; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ODDS RATIO; PERIPHERAL VASCULAR DISEASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTORS, COMPLEMENT 3B; RECEPTORS, INTERLEUKIN-8A; RISK ASSESSMENT; SEX DISTRIBUTION; STATISTICS, NONPARAMETRIC;

EID: 0037298503     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00362-3     Document Type: Article

References (29)

1. Murdoch C., Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood. 95:2000;3032-3043.
2. Reape T.J., Groot P.H. Chemokines and atherosclerosis. Atherosclerosis. 147:1999;213-225.
3. Krieglstein C.F., Granger D.N. Adhesion molecules and their role in vascular disease. Am. J. Hypertens. 14:(6 Part S2):2001;44S-54S.
4. Mantovani A., Bussolino F., Introna M. Cytokine regulation of endothelial cell function: from molecular level to the bedside. Immunol. Today. 18:1997;231-240.
5. 3C motif. Nature. 385:1997;640-644.
6. Chapman G.A., Moores K.E., Gohil J., Berkhout T.A., Patel L., Green P., et al. The role of fractalkine in the recruitment of monocytes to the endothelium. Eur. J. Pharmacol. 392:2000;189-195.
7. 3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J. Immunol. 164:2000;4313-4320.
8. 3CR1, which mediates both leukocyte migration and adhesion. Cell. 91:1997;521-530.
9. Greaves D.R., Hakkinen T., Lucas A.D., Liddiard K., Jones E., Quinn C.M., et al. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 21:2001;923-929.
10. Murphy P.M. The molecular biology of leukocyte chemoattractant receptors. Annu. Rev. Immunol. 12:1994;593-633.
11. Yoneda O., Imai T., Goda S., Inoue H., Yamauchi A., Okazaki T., et al. Fractalkine-mediated endothelial cell injury by NK cells. J. Immunol. 164:2000;4055-4062.
12. 3CR1-expressing microglia. Proc. Natl. Acad. Sci. USA. 95:1998;10896-10901.
13. Cambien B., Pomeranz M., Schmid-Antomarchi H., Millet M.A., Breittmayer V., Rossi B., et al. Signal transduction pathways involved in soluble fractalkine-induced monocytic cell adhesion. Blood. 97:2001;2031-2037.
14. 3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J. Exp. Med. 188:1998;1413-1419.
15. 3CR1. Science. 287:2000;2274-2277.
16. 3CR1 as a genetic risk factor for coronary artery disease. Blood. 97:2001;1925-1928.
17. 3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ. Res. 89:2001;401-407.
18. Sanchez L.A., Veith F.J. Diagnosis and treatment of chronic lower extremity ischemia. Vasc. Med. 3:1998;291-309.
19. 3CR-1 and fractalkine: new factors in the atherosclerosis drama? Circ. Res. 89:2001;376-377.
20. Umehara H., Bloom E., Okazaki T., Domae N., Imai T. Fractalkine and vascular injury. Trends Immunol. 22:2001;602-607.
21. McDermott M.M., Fried L., Simonsick, Ling S., Guralnik. Asymptomatic peripheral arterial disease is independently associated with impaired lower extremity functioning: the women's health and aging study. Circulation. 101:2000;1007-1012.
22. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Int Angiol. 2000;19(I-XXIV):1-304.
23. Renner W., Brodmann M., Winkler M., Washer T.C., Pilger E. The PLA1/A2 polymorphism of platelet glycoprotein IIIa is not associated with peripheral arterial disease. Thromb. Haemost. 85:2001;745-746.
24. Renner W., Schallmoser K., Gallippi P., Krauss C., Toplak H., Wascher T.C., et al. C242T polymorphism of the p22 phox gene is not associated with peripheral arterial occlusive disease. Atherosclerosis. 152:(1):2000;175-179.
25. Raychaudhuri S.P., Jiang W.Y., Farber E.M. Cellular localization of fractalkine at sites of inflammation: antigen-presenting cells in psoriasis express high levels of fractalkine. Br. J. Dermatol. 144:2001;1105-1113.
26. Furuichi K., Wada T., Iwata Y., Sakai N., Yoshimoto K., Shimizu M., et al. Upregulation of fractalkine in human crescentic glomerulonephritis. Nephron. 87:2001;314-320.
27. Muehlhoefer A., Saubermann L.J., Gu X., Luedtke-Heckenkamp K., Xavier R., Blumberg R.S., et al. Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. J. Immunol. 164:2000;3368-3376.
28. 3CR1 rapid communication. Kidney Int. 56:1999;612-620.
29. Epstein S.E., Zhou Y.F., Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation. 100:1999;e20-e28.